Physician profile
David Broomall
NPI 1164469144
$1,374.28
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $251 · 2020: $201 · 2021: $221 · 2022: $457 · 2023: $245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $244.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $402.68 | 2019-2023 | Skyrizi |
| Almirall LLC | $147.54 | 2019-2023 | Klisyri, Seysara |
| Incyte Corporation | $133.08 | 2022-2023 | Opzelura |
| Novartis Pharmaceuticals Corporation | $111.74 | 2019-2021 | |
| Janssen Biotech, INC. | $97.94 | 2020-2022 | |
| Lilly USA, LLC | $78.17 | 2019-2022 | |
| Galderma Laboratories, L.P. | $73.15 | 2021-2022 | |
| Pfizer INC. | $59.71 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $46.10 | 2022-2023 | Dupixent |
| Amgen INC. | $45.24 | 2022-2023 | Otezla |
| Sun Pharmaceutical Industries INC. | $39.17 | 2022-2023 | Ilumya |
| Vyne Pharmaceuticals INC. | $32.49 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.69 | 2022 | |
| Mylan Pharmaceuticals INC. | $26.19 | 2019 | |
| Ucb, INC. | $18.88 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $18.26 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $15.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Broomall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.